SlideShare a Scribd company logo
1 of 24
Download to read offline
Take Back Programs as Part of the Solution to the Prevention of Prescription Drug Abuse 
Dr. Jeanie Jaramillo 
Director, Medication Cleanout™ 
Managing Director, Texas Panhandle Poison Center 
Assistant Professor, Texas Tech University Health Sciences Center School of Pharmacy 
30th Annual Conference 
Savannah, GA 
October 21-24, 2014
What is a “take back” program? 
•The definition of medication “take back” programs vary 
•Generally, a medication take back program is some variation of a periodic event in which unused, expired, or no longer needed medications are collected for disposal 
•Programs vary in who they accept items from (i.e. the public vs. clinics, nursing homes, etc. or a combination)
What requirements are there for take back programs? 
•Rules and requirements vary by state 
•Include local, state, and Federal 
–Law enforcement 
–Environmental 
–Department of transportation 
–State board of pharmacy
Take Back Programs 
What they can do: 
•Remove unused meds from homes 
•Increase public awareness of home meds as source for abuse & poisonings 
•Provide info/data on availability of meds in homes – what’s out there? 
•Address ONE source of meds – i.e. homes/med cabinets 
What they can’t do: 
•Keep people from doctor shopping for the purpose of abusing or diverting meds 
•Stop physicians from knowingly and willingly overprescribing medications for abuse purposes (i.e. pill mills) 
•Provide any info regarding people who use all of their meds or do not participate in take back programs
Medication Cleanout™ 
•Program to allow households to bring meds for appropriate disposal 
•Began in 2009 with Amarillo Police Department, Amarillo Independent School District, Texas Tech School of Pharmacy 
•Combination poison prevention, abuse/crime prevention, research effort 
•2010 received HHS/HRSA Poison Center Incentive Grant - $100K X 3 years; economy tanked; years 2 & 3 were pulled 
•Program continued on minimal funds
Medication Cleanout™ 
•35 events to date across the Texas panhandle 
•20,229 pounds of unused meds collected 
–1,344 pounds of controlled substances (7%) 
–18,885 pounds of non-controlled substances (93%) 
•832 pounds of sharps
296 
725 
1276 
1189 
2010 
1966 
0 
500 
1000 
1500 
2000 
2500 
2009 
2010 
2011 
2012 
2013 
2014 
Number of Participants
796 
852 
3108 
3234 
5226 
4760 
0 
1000 
2000 
3000 
4000 
5000 
6000 
2009 
2010 
2011 
2012 
2013 
2014 
Non-controls in Pounds
Controls in Pounds 
68 
157 
263 
206 
317 
333 
0 
50 
100 
150 
200 
250 
300 
350 
400 
2009 
2010 
2011 
2012 
2013 
2014
Looks Good – Has It Helped? 
•Texas Prevention Impact Index (TPII) – collects data specific to 41 county West Texas region (Region 1) 
•Misuse & abuse of prescription drugs by students in Amarillo ISD has declined over the last 3 years counter to national trend 
•Participants reported that parents and peers disapprove of abuse of prescription meds over that of tobacco, alcohol, and marijuana 
•Many other confounders to consider
What other data does Medication Cleanout collect? 
Data entry screen from Pharmaceutical Collection Monitoring System™ (PCMS) 
www.cas-co.com
Medication 
# of Containers 
Unused % 
pentazocine (e.g. Talwin) 
54 
91% 
methadone 
30 
88% 
butorphanol (Stadol) 
36 
87% 
androgen (testosterone) 
111 
87% 
benzodiazepines (Xanax,etc) 
1585 
85% 
fentanyl 
204 
85% 
morphine 
232 
85% 
buprenorphine (suboxone) 
14 
82% 
meperidine (Demerol) 
14 
81% 
other sedative/hypnotic 
574 
80% 
Controlled Substances Collected – 
Portion Unused as Compared to Originally Filled 
Results compiled from PCMS™ using ToxiCALL® Data Analysis by Computer Automation Systems, Inc.
Medication 
# of Containers 
Unused % 
propoxyphene (Darvon) 
15 
78% 
diphenoxylate/atropine (Lomotil) 
199 
78% 
tramadol* 
147 
77% 
other GABA anticonvulsant (Lyrica) 
415 
75% 
hydrocodone/ APAP (Lortab) 
3593 
69% 
APAP/ other adult formulation 
49 
68% 
APAP/ propoxyphene** (Darvocet) 
1178 
68% 
Hydromorphone (Dilaudid) 
25 
68% 
Carisoprodol (Soma) 
129 
68% 
APAP/ codeine 
415 
65% 
hydrocodone alone or combo other than APAP 
109 
62% 
*tramadol became controlled in Texas 8/14/14 (most tramadol appears as non-controlled) 
** FDA recommended against continued prescribing of propoxyphene 11/19/10
Medication 
# of Containers 
Unused % 
amphetamine and related compound 
167 
61% 
APAP/ oxycodone 
109 
58% 
antihist/decon/codeine 
179 
58% 
APAP/ other opioid* 
37 
56% 
antihist/decon/hydrocod 
296 
55% 
codeine products 
249 
52% 
methylphenidate 
166 
48% 
phenobarbital 
38 
46% 
THC pharmaceuticals 
8 
45% 
oxycodone 
4 
38% 
*APAP/tramadol & apap/pentazocine
So, what does all of this mean? 
•Significant overprescribing is occurring 
•Patients are being prescribed greater quantities than they need; particularly with controlled substances 
•In many cases, physicians could be prescribing HALF the amount of controlled substances 
•Prescribe less with refills, if needed, to avoid accumulation of unneeded medications in the home
How do we use this information? 
•Publish data in medical literature 
•Educate healthcare community to include physicians, pharmacists, nurse practitioners, etc. 
•Advocate for changes in the healthcare industry – prescribing large quantities of medications for minor procedures should not be acceptable 
•Consider 15 day limits (MaineCare model) on initial prescriptions for: 
–medications frequently discontinued due to side effects, 
–medications with high discontinuation rates, 
–medications with frequent dose adjustments 
•Ensure cost effectiveness without wasting or discarding medications
Educate the Public 
•Let consumers know that keeping excess meds in the home presents a risk 
•Educate consumers that they can ask their pharmacy for a “partial fill” of a medication 
•Remind them to safeguard medications, especially controls (lock them up if possible – monitor them otherwise) 
•Talk to their children about the dangers of prescription abuse
More Data Needed 
•Pharmaceutical system in the U.S. is broken 
•Auto-refills and mail order are leading to large accumulations of meds in homes 
•Ludicrous that refills can be distributed without a patient confirming that: 
a)They still use the medication and, 
b)They need more of it. 
•This is costing the healthcare industry (and tax payers) billions of dollars a year
More Importantly 
•This is costing people their lives! 
–Not just in terms of life and death 
–Quality of life 
–Addiction 
–Gateway to other drugs of abuse
Car 188 
These medications were brought in by the adult son of a deceased couple, both of whom speculatively died of cancer. The labels on these meds indicated that they were primarily from a mail-order pharmacy. Many of these meds were unopened. This photograph included only the non-controlled substances from Car 188. The next two slides detail quantities of both the collected controls and non- controls.
Car 188 – Case Example 
Product: Strength: Quantity: Est. Value: 
diazepam 5 2385 $140.12 
hydrocodone/apap 10/325 500 $349.50 
hydrocodone/apap 5/500 22 $3.11 
Lyrica 75 84 $235.68 
morphine 30 6699 $3,678.58 
morphine 15 3338 $966.90 
MS Contin 30 3 $9.36 
MS Contin 15 6 $9.85 
oxycodone/apap 5/500 802 $322.81 
temazepam 30 180 $90.09 
carisoprodol 350 50 $50.00 
TOTAL 14069 $5,855.99 
Controlled Substances 
Estimated street value $385,000 (Based on 2011 National Drug Intelligence Center values)
Car 188 – Case Example 
Product: Quantity: Est. Value: Product: Quantity: Est. Value: 
Antacids 446 $2,428.81 Hormones/antagonists 2568 $666.22 
Antibiotics 405 $1,177.04 Miscellaneous 3527 $5,768.70 
Anticholinergic drugs 168 $3,680.93 MVI: adult 91 $83.54 
Anticoagulants 3977 $4,064.26 Cyclobenzaprine 356 $538.53 
Antidepressants 570 $2,595.63 Methocarbamol 419 $714.67 
Antifungal 245 $326.28 Other skeletal muscle relaxant 3868 $5,575.44 
Antihistamine 6067 $6,456.57 Opioids (tramadol) 1279 $2,713.26 
Antineoplastics 20 $423.16 Oral hypoglycemic: biguanide 79.5 $94.01 
Antiparasitics 745.5 $1,078.09 Colchicine 14 $4.44 
Asthma therapies 1736 $8,508.77 Ibuprofen 93 $5.13 
Cardiovascular 6020.5 $11,096.50 Indomethacin 13 $30.36 
Cyclic Antidepressants 232 $248.06 Naproxen 248 $568.09 
Diuretics 951 $203.76 Other B complex vitamins 134 $148.23 
Electrolytes 64 $25.49 Buspirone 49 $97.54 
Gastrointestinal 388 $118.99 Phenothiazine 115 $87.44 
TOTAL 34889 $59,527.91 
Non-Controlled Rx Substances 
2011 WAC where available; otherwise, AWP
Contact Information 
Jeanie Jaramillo, PharmD 
jeanie.jaramillo@ttuhsc.edu 
Texas Panhandle Poison Center/TTUHSC SOP 
1300 S. Coulter, Suite 105 
Amarillo, TX 79106 
(806) 414-9402 
www.MedicationCleanout.com 
(806)414-9495
Computer Automation Systems, Inc. Aurora, Colorado www.cas-co.com info@cas-co.com (303) 680-7774 
The Pharmaceutical Collection Monitoring System™ (PCMS) is a web- based data collection tool developed by Computer Automation Systems, Inc. PCMS utilizes an interface with Micromedex® Solutions as a resource for the consistent categorization and collection of medication-related information for research and reporting purposes. 
ToxiCALL® Data Analysis, also developed by Computer Automation Systems, Inc., is an analysis and reporting tool that allows for user- defined reporting and/or analysis of PCMS data on demand.

More Related Content

What's hot

Pharmacy and therapeutics committee
Pharmacy and therapeutics committeePharmacy and therapeutics committee
Pharmacy and therapeutics committeeRavish Yadav
 
Safe Prescribing Practices Conference for Medical Professionals, June 2013
Safe Prescribing Practices Conference for Medical Professionals, June 2013Safe Prescribing Practices Conference for Medical Professionals, June 2013
Safe Prescribing Practices Conference for Medical Professionals, June 2013Heidi Denton
 
Rx16 vs nadcp_tues_800_1_walton
Rx16 vs nadcp_tues_800_1_waltonRx16 vs nadcp_tues_800_1_walton
Rx16 vs nadcp_tues_800_1_waltonOPUNITE
 
Forensic pharmacovigilance: Newer dimension of pharmacovigilance
Forensic pharmacovigilance: Newer dimension of pharmacovigilanceForensic pharmacovigilance: Newer dimension of pharmacovigilance
Forensic pharmacovigilance: Newer dimension of pharmacovigilanceRosmirella Cano Rojas
 
Drug and therapeutic committee
Drug and therapeutic committee Drug and therapeutic committee
Drug and therapeutic committee Jisa Anna M
 
AN OVERVIEW ON PHARMACO THERAPEUTIC COMMITTEE - M.L.SUSHMITHA
AN OVERVIEW ON PHARMACO THERAPEUTIC COMMITTEE - M.L.SUSHMITHAAN OVERVIEW ON PHARMACO THERAPEUTIC COMMITTEE - M.L.SUSHMITHA
AN OVERVIEW ON PHARMACO THERAPEUTIC COMMITTEE - M.L.SUSHMITHAlakshmisushmitha2
 
Rx15 vision tues_200_pew_1_reilly_2wendt_3kachur_4nader
Rx15 vision tues_200_pew_1_reilly_2wendt_3kachur_4naderRx15 vision tues_200_pew_1_reilly_2wendt_3kachur_4nader
Rx15 vision tues_200_pew_1_reilly_2wendt_3kachur_4naderOPUNITE
 
Rx15 vi sion_tues_800_ameritox
Rx15 vi sion_tues_800_ameritoxRx15 vi sion_tues_800_ameritox
Rx15 vi sion_tues_800_ameritoxOPUNITE
 
Urine Toxicology Testing
Urine Toxicology TestingUrine Toxicology Testing
Urine Toxicology Testingyury
 
Establishing a drug information center
Establishing a drug information centerEstablishing a drug information center
Establishing a drug information centerkatta amulya
 
Spontaneous reporting schemes for biodrug adverse reactions,
Spontaneous reporting schemes for biodrug adverse reactions,Spontaneous reporting schemes for biodrug adverse reactions,
Spontaneous reporting schemes for biodrug adverse reactions,Vishwajeet Upadhye
 
Proper Disposal of Unwanted Medicines with a Focus on the Aging. Source:U.S. ...
Proper Disposal of Unwanted Medicines with a Focus on the Aging. Source:U.S. ...Proper Disposal of Unwanted Medicines with a Focus on the Aging. Source:U.S. ...
Proper Disposal of Unwanted Medicines with a Focus on the Aging. Source:U.S. ...SerPIE Repository
 
High cost of medications in colombia
High cost of medications in colombiaHigh cost of medications in colombia
High cost of medications in colombiaRubashkyn
 
Drugs used in special populations | Geriatric | Pediatric patients | Pregnant...
Drugs used in special populations | Geriatric | Pediatric patients | Pregnant...Drugs used in special populations | Geriatric | Pediatric patients | Pregnant...
Drugs used in special populations | Geriatric | Pediatric patients | Pregnant...Shaikh Abusufyan
 
PHARMACY AND THERAPEUTIC COMMITTEE
PHARMACY AND THERAPEUTIC COMMITTEEPHARMACY AND THERAPEUTIC COMMITTEE
PHARMACY AND THERAPEUTIC COMMITTEERamesh Ganpisetti
 
forensic urine drug testing
forensic urine drug testingforensic urine drug testing
forensic urine drug testingDinaadday
 
the extent of the medications error problem
  the extent of the medications error problem  the extent of the medications error problem
the extent of the medications error problemMEEQAT HOSPITAL
 

What's hot (20)

ADR REPORTING
ADR REPORTINGADR REPORTING
ADR REPORTING
 
Pharmacy and therapeutics committee
Pharmacy and therapeutics committeePharmacy and therapeutics committee
Pharmacy and therapeutics committee
 
Safe Prescribing Practices Conference for Medical Professionals, June 2013
Safe Prescribing Practices Conference for Medical Professionals, June 2013Safe Prescribing Practices Conference for Medical Professionals, June 2013
Safe Prescribing Practices Conference for Medical Professionals, June 2013
 
Ptc pradeep
Ptc  pradeepPtc  pradeep
Ptc pradeep
 
Rx16 vs nadcp_tues_800_1_walton
Rx16 vs nadcp_tues_800_1_waltonRx16 vs nadcp_tues_800_1_walton
Rx16 vs nadcp_tues_800_1_walton
 
Forensic pharmacovigilance: Newer dimension of pharmacovigilance
Forensic pharmacovigilance: Newer dimension of pharmacovigilanceForensic pharmacovigilance: Newer dimension of pharmacovigilance
Forensic pharmacovigilance: Newer dimension of pharmacovigilance
 
Drug and therapeutic committee
Drug and therapeutic committee Drug and therapeutic committee
Drug and therapeutic committee
 
AN OVERVIEW ON PHARMACO THERAPEUTIC COMMITTEE - M.L.SUSHMITHA
AN OVERVIEW ON PHARMACO THERAPEUTIC COMMITTEE - M.L.SUSHMITHAAN OVERVIEW ON PHARMACO THERAPEUTIC COMMITTEE - M.L.SUSHMITHA
AN OVERVIEW ON PHARMACO THERAPEUTIC COMMITTEE - M.L.SUSHMITHA
 
Rx15 vision tues_200_pew_1_reilly_2wendt_3kachur_4nader
Rx15 vision tues_200_pew_1_reilly_2wendt_3kachur_4naderRx15 vision tues_200_pew_1_reilly_2wendt_3kachur_4nader
Rx15 vision tues_200_pew_1_reilly_2wendt_3kachur_4nader
 
Rx15 vi sion_tues_800_ameritox
Rx15 vi sion_tues_800_ameritoxRx15 vi sion_tues_800_ameritox
Rx15 vi sion_tues_800_ameritox
 
Urine Toxicology Testing
Urine Toxicology TestingUrine Toxicology Testing
Urine Toxicology Testing
 
Establishing a drug information center
Establishing a drug information centerEstablishing a drug information center
Establishing a drug information center
 
Spontaneous reporting schemes for biodrug adverse reactions,
Spontaneous reporting schemes for biodrug adverse reactions,Spontaneous reporting schemes for biodrug adverse reactions,
Spontaneous reporting schemes for biodrug adverse reactions,
 
Proper Disposal of Unwanted Medicines with a Focus on the Aging. Source:U.S. ...
Proper Disposal of Unwanted Medicines with a Focus on the Aging. Source:U.S. ...Proper Disposal of Unwanted Medicines with a Focus on the Aging. Source:U.S. ...
Proper Disposal of Unwanted Medicines with a Focus on the Aging. Source:U.S. ...
 
One pill can kill
One pill can killOne pill can kill
One pill can kill
 
High cost of medications in colombia
High cost of medications in colombiaHigh cost of medications in colombia
High cost of medications in colombia
 
Drugs used in special populations | Geriatric | Pediatric patients | Pregnant...
Drugs used in special populations | Geriatric | Pediatric patients | Pregnant...Drugs used in special populations | Geriatric | Pediatric patients | Pregnant...
Drugs used in special populations | Geriatric | Pediatric patients | Pregnant...
 
PHARMACY AND THERAPEUTIC COMMITTEE
PHARMACY AND THERAPEUTIC COMMITTEEPHARMACY AND THERAPEUTIC COMMITTEE
PHARMACY AND THERAPEUTIC COMMITTEE
 
forensic urine drug testing
forensic urine drug testingforensic urine drug testing
forensic urine drug testing
 
the extent of the medications error problem
  the extent of the medications error problem  the extent of the medications error problem
the extent of the medications error problem
 

Similar to Med Take Back and Rx Abuse PPT

Best Practices in Controlling Prescription Drug Costs
Best Practices in Controlling Prescription Drug CostsBest Practices in Controlling Prescription Drug Costs
Best Practices in Controlling Prescription Drug CostsPSG Consults
 
HOSPITALFORMULARY.pptx
HOSPITALFORMULARY.pptxHOSPITALFORMULARY.pptx
HOSPITALFORMULARY.pptxPunamGauchan1
 
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexanderRx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexanderOPUNITE
 
Polypharmacy in the elderly
Polypharmacy in the elderlyPolypharmacy in the elderly
Polypharmacy in the elderlyMarc Evans Abat
 
Pharmaceutical industry
Pharmaceutical industryPharmaceutical industry
Pharmaceutical industrymohamadtzzaman
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiologylateef khan
 
Rx16 federal tues_330_1_spitznas_2baldwin_3welch
Rx16 federal tues_330_1_spitznas_2baldwin_3welchRx16 federal tues_330_1_spitznas_2baldwin_3welch
Rx16 federal tues_330_1_spitznas_2baldwin_3welchOPUNITE
 
High Drug Costs
High Drug CostsHigh Drug Costs
High Drug Costshrvoboril
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
PharmacovigilanceVignesh K
 
Drug Approval Bodies in Canada 101: The Elevator Length Pitch
Drug Approval Bodies in Canada 101: The Elevator Length PitchDrug Approval Bodies in Canada 101: The Elevator Length Pitch
Drug Approval Bodies in Canada 101: The Elevator Length PitchCanadian Cancer Survivor Network
 
Clinical Pharmacology in Orphan Drug Development
Clinical Pharmacology in Orphan Drug DevelopmentClinical Pharmacology in Orphan Drug Development
Clinical Pharmacology in Orphan Drug DevelopmentE. Dennis Bashaw
 
3.6. Reducing Pharmaceutical Waste in Clinical Care (Kreisberg)
3.6. Reducing Pharmaceutical Waste in Clinical Care (Kreisberg)3.6. Reducing Pharmaceutical Waste in Clinical Care (Kreisberg)
3.6. Reducing Pharmaceutical Waste in Clinical Care (Kreisberg)Teleosis Institute
 
Introduction to rational use of drugs and role of pharmacist in rational use...
Introduction to  rational use of drugs and role of pharmacist in rational use...Introduction to  rational use of drugs and role of pharmacist in rational use...
Introduction to rational use of drugs and role of pharmacist in rational use...Adhin Antony Xavier
 
Wed gs frieden
Wed gs friedenWed gs frieden
Wed gs friedenOPUNITE
 
ethical promotion of drugs.pptx
ethical promotion of drugs.pptxethical promotion of drugs.pptx
ethical promotion of drugs.pptxDrPrasannaDahal
 
Ethical promotion of drugs
Ethical promotion of drugsEthical promotion of drugs
Ethical promotion of drugsprasannadahal
 

Similar to Med Take Back and Rx Abuse PPT (20)

Best Practices in Controlling Prescription Drug Costs
Best Practices in Controlling Prescription Drug CostsBest Practices in Controlling Prescription Drug Costs
Best Practices in Controlling Prescription Drug Costs
 
HOSPITALFORMULARY.pptx
HOSPITALFORMULARY.pptxHOSPITALFORMULARY.pptx
HOSPITALFORMULARY.pptx
 
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexanderRx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
 
Polypharmacy in the elderly
Polypharmacy in the elderlyPolypharmacy in the elderly
Polypharmacy in the elderly
 
Pharmaceutical industry
Pharmaceutical industryPharmaceutical industry
Pharmaceutical industry
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
 
Rx16 federal tues_330_1_spitznas_2baldwin_3welch
Rx16 federal tues_330_1_spitznas_2baldwin_3welchRx16 federal tues_330_1_spitznas_2baldwin_3welch
Rx16 federal tues_330_1_spitznas_2baldwin_3welch
 
Chapter 3
Chapter 3Chapter 3
Chapter 3
 
High Drug Costs
High Drug CostsHigh Drug Costs
High Drug Costs
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
Drug Approval Bodies in Canada 101: The Elevator Length Pitch
Drug Approval Bodies in Canada 101: The Elevator Length PitchDrug Approval Bodies in Canada 101: The Elevator Length Pitch
Drug Approval Bodies in Canada 101: The Elevator Length Pitch
 
Clinical Pharmacology in Orphan Drug Development
Clinical Pharmacology in Orphan Drug DevelopmentClinical Pharmacology in Orphan Drug Development
Clinical Pharmacology in Orphan Drug Development
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
3.6. Reducing Pharmaceutical Waste in Clinical Care (Kreisberg)
3.6. Reducing Pharmaceutical Waste in Clinical Care (Kreisberg)3.6. Reducing Pharmaceutical Waste in Clinical Care (Kreisberg)
3.6. Reducing Pharmaceutical Waste in Clinical Care (Kreisberg)
 
Introduction to rational use of drugs and role of pharmacist in rational use...
Introduction to  rational use of drugs and role of pharmacist in rational use...Introduction to  rational use of drugs and role of pharmacist in rational use...
Introduction to rational use of drugs and role of pharmacist in rational use...
 
Wed gs frieden
Wed gs friedenWed gs frieden
Wed gs frieden
 
ethical promotion of drugs.pptx
ethical promotion of drugs.pptxethical promotion of drugs.pptx
ethical promotion of drugs.pptx
 
Ethical promotion of drugs
Ethical promotion of drugsEthical promotion of drugs
Ethical promotion of drugs
 
Medication safety 2011
Medication safety 2011Medication safety 2011
Medication safety 2011
 

Med Take Back and Rx Abuse PPT

  • 1. Take Back Programs as Part of the Solution to the Prevention of Prescription Drug Abuse Dr. Jeanie Jaramillo Director, Medication Cleanout™ Managing Director, Texas Panhandle Poison Center Assistant Professor, Texas Tech University Health Sciences Center School of Pharmacy 30th Annual Conference Savannah, GA October 21-24, 2014
  • 2. What is a “take back” program? •The definition of medication “take back” programs vary •Generally, a medication take back program is some variation of a periodic event in which unused, expired, or no longer needed medications are collected for disposal •Programs vary in who they accept items from (i.e. the public vs. clinics, nursing homes, etc. or a combination)
  • 3. What requirements are there for take back programs? •Rules and requirements vary by state •Include local, state, and Federal –Law enforcement –Environmental –Department of transportation –State board of pharmacy
  • 4. Take Back Programs What they can do: •Remove unused meds from homes •Increase public awareness of home meds as source for abuse & poisonings •Provide info/data on availability of meds in homes – what’s out there? •Address ONE source of meds – i.e. homes/med cabinets What they can’t do: •Keep people from doctor shopping for the purpose of abusing or diverting meds •Stop physicians from knowingly and willingly overprescribing medications for abuse purposes (i.e. pill mills) •Provide any info regarding people who use all of their meds or do not participate in take back programs
  • 5. Medication Cleanout™ •Program to allow households to bring meds for appropriate disposal •Began in 2009 with Amarillo Police Department, Amarillo Independent School District, Texas Tech School of Pharmacy •Combination poison prevention, abuse/crime prevention, research effort •2010 received HHS/HRSA Poison Center Incentive Grant - $100K X 3 years; economy tanked; years 2 & 3 were pulled •Program continued on minimal funds
  • 6. Medication Cleanout™ •35 events to date across the Texas panhandle •20,229 pounds of unused meds collected –1,344 pounds of controlled substances (7%) –18,885 pounds of non-controlled substances (93%) •832 pounds of sharps
  • 7. 296 725 1276 1189 2010 1966 0 500 1000 1500 2000 2500 2009 2010 2011 2012 2013 2014 Number of Participants
  • 8. 796 852 3108 3234 5226 4760 0 1000 2000 3000 4000 5000 6000 2009 2010 2011 2012 2013 2014 Non-controls in Pounds
  • 9. Controls in Pounds 68 157 263 206 317 333 0 50 100 150 200 250 300 350 400 2009 2010 2011 2012 2013 2014
  • 10. Looks Good – Has It Helped? •Texas Prevention Impact Index (TPII) – collects data specific to 41 county West Texas region (Region 1) •Misuse & abuse of prescription drugs by students in Amarillo ISD has declined over the last 3 years counter to national trend •Participants reported that parents and peers disapprove of abuse of prescription meds over that of tobacco, alcohol, and marijuana •Many other confounders to consider
  • 11. What other data does Medication Cleanout collect? Data entry screen from Pharmaceutical Collection Monitoring System™ (PCMS) www.cas-co.com
  • 12. Medication # of Containers Unused % pentazocine (e.g. Talwin) 54 91% methadone 30 88% butorphanol (Stadol) 36 87% androgen (testosterone) 111 87% benzodiazepines (Xanax,etc) 1585 85% fentanyl 204 85% morphine 232 85% buprenorphine (suboxone) 14 82% meperidine (Demerol) 14 81% other sedative/hypnotic 574 80% Controlled Substances Collected – Portion Unused as Compared to Originally Filled Results compiled from PCMS™ using ToxiCALL® Data Analysis by Computer Automation Systems, Inc.
  • 13. Medication # of Containers Unused % propoxyphene (Darvon) 15 78% diphenoxylate/atropine (Lomotil) 199 78% tramadol* 147 77% other GABA anticonvulsant (Lyrica) 415 75% hydrocodone/ APAP (Lortab) 3593 69% APAP/ other adult formulation 49 68% APAP/ propoxyphene** (Darvocet) 1178 68% Hydromorphone (Dilaudid) 25 68% Carisoprodol (Soma) 129 68% APAP/ codeine 415 65% hydrocodone alone or combo other than APAP 109 62% *tramadol became controlled in Texas 8/14/14 (most tramadol appears as non-controlled) ** FDA recommended against continued prescribing of propoxyphene 11/19/10
  • 14. Medication # of Containers Unused % amphetamine and related compound 167 61% APAP/ oxycodone 109 58% antihist/decon/codeine 179 58% APAP/ other opioid* 37 56% antihist/decon/hydrocod 296 55% codeine products 249 52% methylphenidate 166 48% phenobarbital 38 46% THC pharmaceuticals 8 45% oxycodone 4 38% *APAP/tramadol & apap/pentazocine
  • 15. So, what does all of this mean? •Significant overprescribing is occurring •Patients are being prescribed greater quantities than they need; particularly with controlled substances •In many cases, physicians could be prescribing HALF the amount of controlled substances •Prescribe less with refills, if needed, to avoid accumulation of unneeded medications in the home
  • 16. How do we use this information? •Publish data in medical literature •Educate healthcare community to include physicians, pharmacists, nurse practitioners, etc. •Advocate for changes in the healthcare industry – prescribing large quantities of medications for minor procedures should not be acceptable •Consider 15 day limits (MaineCare model) on initial prescriptions for: –medications frequently discontinued due to side effects, –medications with high discontinuation rates, –medications with frequent dose adjustments •Ensure cost effectiveness without wasting or discarding medications
  • 17. Educate the Public •Let consumers know that keeping excess meds in the home presents a risk •Educate consumers that they can ask their pharmacy for a “partial fill” of a medication •Remind them to safeguard medications, especially controls (lock them up if possible – monitor them otherwise) •Talk to their children about the dangers of prescription abuse
  • 18. More Data Needed •Pharmaceutical system in the U.S. is broken •Auto-refills and mail order are leading to large accumulations of meds in homes •Ludicrous that refills can be distributed without a patient confirming that: a)They still use the medication and, b)They need more of it. •This is costing the healthcare industry (and tax payers) billions of dollars a year
  • 19. More Importantly •This is costing people their lives! –Not just in terms of life and death –Quality of life –Addiction –Gateway to other drugs of abuse
  • 20. Car 188 These medications were brought in by the adult son of a deceased couple, both of whom speculatively died of cancer. The labels on these meds indicated that they were primarily from a mail-order pharmacy. Many of these meds were unopened. This photograph included only the non-controlled substances from Car 188. The next two slides detail quantities of both the collected controls and non- controls.
  • 21. Car 188 – Case Example Product: Strength: Quantity: Est. Value: diazepam 5 2385 $140.12 hydrocodone/apap 10/325 500 $349.50 hydrocodone/apap 5/500 22 $3.11 Lyrica 75 84 $235.68 morphine 30 6699 $3,678.58 morphine 15 3338 $966.90 MS Contin 30 3 $9.36 MS Contin 15 6 $9.85 oxycodone/apap 5/500 802 $322.81 temazepam 30 180 $90.09 carisoprodol 350 50 $50.00 TOTAL 14069 $5,855.99 Controlled Substances Estimated street value $385,000 (Based on 2011 National Drug Intelligence Center values)
  • 22. Car 188 – Case Example Product: Quantity: Est. Value: Product: Quantity: Est. Value: Antacids 446 $2,428.81 Hormones/antagonists 2568 $666.22 Antibiotics 405 $1,177.04 Miscellaneous 3527 $5,768.70 Anticholinergic drugs 168 $3,680.93 MVI: adult 91 $83.54 Anticoagulants 3977 $4,064.26 Cyclobenzaprine 356 $538.53 Antidepressants 570 $2,595.63 Methocarbamol 419 $714.67 Antifungal 245 $326.28 Other skeletal muscle relaxant 3868 $5,575.44 Antihistamine 6067 $6,456.57 Opioids (tramadol) 1279 $2,713.26 Antineoplastics 20 $423.16 Oral hypoglycemic: biguanide 79.5 $94.01 Antiparasitics 745.5 $1,078.09 Colchicine 14 $4.44 Asthma therapies 1736 $8,508.77 Ibuprofen 93 $5.13 Cardiovascular 6020.5 $11,096.50 Indomethacin 13 $30.36 Cyclic Antidepressants 232 $248.06 Naproxen 248 $568.09 Diuretics 951 $203.76 Other B complex vitamins 134 $148.23 Electrolytes 64 $25.49 Buspirone 49 $97.54 Gastrointestinal 388 $118.99 Phenothiazine 115 $87.44 TOTAL 34889 $59,527.91 Non-Controlled Rx Substances 2011 WAC where available; otherwise, AWP
  • 23. Contact Information Jeanie Jaramillo, PharmD jeanie.jaramillo@ttuhsc.edu Texas Panhandle Poison Center/TTUHSC SOP 1300 S. Coulter, Suite 105 Amarillo, TX 79106 (806) 414-9402 www.MedicationCleanout.com (806)414-9495
  • 24. Computer Automation Systems, Inc. Aurora, Colorado www.cas-co.com info@cas-co.com (303) 680-7774 The Pharmaceutical Collection Monitoring System™ (PCMS) is a web- based data collection tool developed by Computer Automation Systems, Inc. PCMS utilizes an interface with Micromedex® Solutions as a resource for the consistent categorization and collection of medication-related information for research and reporting purposes. ToxiCALL® Data Analysis, also developed by Computer Automation Systems, Inc., is an analysis and reporting tool that allows for user- defined reporting and/or analysis of PCMS data on demand.